Unum Therapeutics, a biotech out of Cambridge, Massachusetts which is developing a universal cellular immunotherapy to treat multiple cancers, has hired Geoffrey Hodge as Senior Vice President, Operations, effective immediately. Mr. Hodge will be responsible for leading both technical operations, including process development and manufacturing of the company’s proprietary antibody-coupled T-cell receptor (ACTR) therapies, and non-technical operations at Unum.
“Geoff has tremendous experience leading novel clinical manufacturing processes and establishing quality and regulatory standards. We look forward to leveraging this expertise at Unum.”
“As we continue to build out our engineered T-cell pipeline and evolve our clinical-stage programs, Geoff’s bioprocessing acumen will be critical to Unum,” said Chuck Wilson, PhD, President & CEO of Unum Therapeutics. “Geoff has tremendous experience leading novel clinical manufacturing processes and establishing quality and regulatory standards. We look forward to leveraging this expertise at Unum.”
Mr. Hodge has over 25 years of experience in the biotechnology industry, leading bioprocessing efforts for companies including Millennium Pharmaceuticals (now Takeda), Genetics Institute (now Pfizer) and Alpha-Beta Technology. He was a co-founder of Xcellerex, a company specializing in single-use bioreactors, mixers and facilities, as well as process development and GMP manufacturing services using single-use biomanufacturing systems. Through his work at Xcellerex, he is the inventor of record on multiple technology patents.
Most recently, Mr. Hodge served as the Bioprocess Technology Leader at GE Healthcare Life Sciences. In this role, he was responsible for providing technical expertise to bioprocess customers to help them address their technical needs with the optimal combination of products and services.
“I am really excited to be a part of Unum’s management team,” said Mr. Hodge. “Unum has the full package—a unique platform with the potential to address critical unmet medical needs and a smart and experienced leadership team. The potential of the company is clearly evidenced by the recent oversubscribed Series B financing as well as the collaboration and license agreement with Seattle Genetics. I look forward to being a part of its future achievements.”
Mr. Hodge received his BA in Biology from Colgate University, and his MS in Biotechnology from Worcester Polytechnic Institute.
About Unum Therapeutics
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, recently entered Phase 1 clinical testing to assess safety and efficacy. The company is headquartered in Cambridge, MA.